These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 30585388)

  • 1. Effect of early tirofiban administration on N-terminal pro-B-type natriuretic peptide level in patients treated with primary percutaneous coronary intervention.
    Fabris E; Ottervanger JP; Hermanides RS; Ten Berg JM; Sinagra G; Koopmans PC; Giannitsis E; Hamm C; van 't Hof AWJ
    Catheter Cardiovasc Interv; 2019 Apr; 93(5):E293-E297. PubMed ID: 30585388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NT-proBNP level before primary PCI and risk of poor myocardial reperfusion: Insight from the On-TIME II trial.
    Fabris E; Ten Berg JM; Hermanides RS; Ottervanger JP; Dambrink JHE; Gosselink AM; Sinagra G; Koopmans PC; Giannitsis E; Hamm C; van 't Hof AWJ
    Am Heart J; 2021 Mar; 233():78-85. PubMed ID: 33388289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term mortality and prehospital tirofiban treatment in patients with ST elevation myocardial infarction.
    Fabris E; Kilic S; Schellings DAAM; Ten Berg JM; Kennedy MW; van Houwelingen KG; Giannitsis E; Kolkman E; Ottervanger JP; Hamm C; Van't Hof AWJ
    Heart; 2017 Oct; 103(19):1515-1520. PubMed ID: 28679686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early discharge after primary percutaneous coronary intervention: the added value of N-terminal pro-brain natriuretic peptide to the Zwolle Risk Score.
    Schellings DA; Adiyaman A; Giannitsis E; Hamm C; Suryapranata H; Ten Berg JM; Hoorntje JC; Van't Hof AW
    J Am Heart Assoc; 2014 Nov; 3(6):e001089. PubMed ID: 25389283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: a substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trial.
    Jarai R; Huber K; Bogaerts K; Droogne W; Ezekowitz J; Granger CB; Sinnaeve PR; Ross AM; Zeymer U; Armstrong PW; Van de Werf FJ;
    Am Heart J; 2010 Jan; 159(1):131-40. PubMed ID: 20102879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracoronary compared with intravenous bolus tirofiban on the microvascular obstruction in patients with STEMI undergoing PCI: a cardiac MR study.
    Ma Q; Ma Y; Wang X; Li S; Yu T; Duan W; Wu J; Wen Z; Jiao Y; Sun Z; Hou Y
    Int J Cardiovasc Imaging; 2020 Jun; 36(6):1121-1132. PubMed ID: 32078096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-terminal pro-B-type natriuretic peptide is associated with adverse short-term clinical outcomes in patients with acute ST-elevation myocardial infarction underwent primary percutaneous coronary intervention.
    Kwon TG; Bae JH; Jeong MH; Kim YJ; Hur SH; Seong IW; Cho MC; Seung KB; Jang YS; Park SJ;
    Int J Cardiol; 2009 Apr; 133(2):173-8. PubMed ID: 18281115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association of baseline N-terminal pro-B-type natriuretic peptide with short and long-term prognosis following percutaneous coronary intervention in non-ST segment elevation acute coronary syndrome with multivessel coronary artery disease: a retrospective cohort study.
    He WF; Jiang L; Chen YY; Liu YH; Chen PY; Duan CY; Zeng LH; Fan HL; Wei XB; Guo W; Chen W; Li J; Li WS; Guo ZQ; Liu ZK; Tan N; Chen JY; He PC
    BMC Cardiovasc Disord; 2021 Apr; 21(1):202. PubMed ID: 33882836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of pre-hospital glycoprotein IIb-IIIa inhibitors on angiographic outcome in STEMI patients who are candidates for primary PCI.
    Hermanides RS; van Werkum JW; Ottervanger JP; Breet NJ; Gosselink AT; van Houwelingen KG; Dambrink JH; Hamm C; ten Berg JM; van 't Hof AW;
    Catheter Cardiovasc Interv; 2012 May; 79(6):956-64. PubMed ID: 22162050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of NT-proBNP on admission for early risk stratification of patients undergoing primary percutaneous coronary intervention.
    Ayhan E; Isık T; Uyarel H; Ergelen M; Cicek G; Ozyurtlu F; Ghannadian B; Tanboga IH
    Kardiol Pol; 2013; 71(2):165-75. PubMed ID: 23575711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved early risk stratification of patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention using a combination of serum soluble ST2 and NT-proBNP.
    Yu J; Oh PC; Kim M; Moon J; Park YM; Lee K; Suh SY; Han SH; Byun K; Ahn T; Kang WC
    PLoS One; 2017; 12(8):e0182829. PubMed ID: 28796845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of systemic immune-inflammation index combined with N-terminal pro-brain natriuretic peptide for contrast-induced acute kidney injury in patients with STEMI after primary PCI.
    Shen G; He H; Zhang X; Wang L; Wang Z; Li F; Lu Y; Li W
    Int Urol Nephrol; 2024 Mar; 56(3):1147-1156. PubMed ID: 37658947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into the change in brain natriuretic peptide after ST-elevation myocardial infarction (STEMI): why should it be better than baseline?
    Ezekowitz JA; Théroux P; Welsh R; Bata I; Webb J; Armstrong PW
    Can J Physiol Pharmacol; 2007 Jan; 85(1):173-8. PubMed ID: 17487257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysis.
    Sinnaeve PR; Ezekowitz JA; Bogaerts K; Droogne W; Jarai R; Huber K; Granger CB; Desmet WJ; Armstrong PW; Van de Werf FJ;
    Eur Heart J; 2009 Sep; 30(18):2213-9. PubMed ID: 19586960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction.
    Heestermans AA; Van Werkum JW; Hamm C; Dill T; Gosselink AT; De Boer MJ; Van Houwelingen G; Hoorntje JC; Koopmans PC; Ten Berg JM; Van 't Hof AW
    J Thromb Haemost; 2009 Oct; 7(10):1612-8. PubMed ID: 19682233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-Terminal Fragment of Pro B-type Natriuretic Peptide as a Marker of Contrast-Induced Nephropathy After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction.
    Goussot S; Mousson C; Guenancia C; Stamboul K; Brunel P; Brunet D; Touzery C; Cottin Y; Zeller M
    Am J Cardiol; 2015 Sep; 116(6):865-71. PubMed ID: 26183794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NT-proANP and NT-proBNP circulating levels as predictors of cardiovascular outcome following coronary stent implantation.
    Niccoli G; Conte M; Marchitti S; Montone RA; Fracassi F; Grippo R; Roberto M; Burzotta F; Trani C; Leone AM; Bianchi F; Di Castro S; Volpe M; Crea F; Rubattu S
    Cardiovasc Revasc Med; 2016; 17(3):162-8. PubMed ID: 26987266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of GP IIb/IIIa inhibitor duration on the clinical prognosis of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction with no-/slow-reflow phenomenon.
    Hu X; Wang W; Ye J; Lin Y; Yu B; Zhou L; Zhou Y; Dong H
    Biomed Pharmacother; 2021 Nov; 143():112196. PubMed ID: 34560551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Biomarkers, ST-Elevation Resolution, and Clinical Outcomes Following Primary Percutaneous Coronary Intervention.
    Shavadia JS; Granger CB; Alemayehu W; Westerhout CM; Povsic TJ; Van Diepen S; Defilippi C; Armstrong PW
    J Am Heart Assoc; 2020 Jul; 9(13):e016033. PubMed ID: 32552321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal pro-B-type natriuretic peptide: a Clopidogrel for the Reduction of Events During Observation (CREDO) substudy.
    Tang WH; Steinhubl SR; Van Lente F; Brennan D; McErlean E; Maroo A; Francis GS; Topol EJ
    Am Heart J; 2007 Jan; 153(1):36-41. PubMed ID: 17174634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.